Last reviewed · How we verify
Echinacea purpurea
Echinacea purpurea is a Biologic drug developed by University of Washington. It is currently FDA-approved.
At a glance
| Generic name | Echinacea purpurea |
|---|---|
| Sponsor | University of Washington |
| Modality | Biologic |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Evaluation of Performance and Safety of Carbopol 980 NF 0.2%- Based Medical Device in the Management of Patients With Glaucomar or Ocular Hypertension and Concomitant Dry Eye Syndrome on Multiple Long-term Topical Hypotensive Therapy (NA)
- Assessing the Impact of Herbal Supplement on Fatigue and Disease Activity in SLE: Results From an 8-Week Randomized Trial (NA)
- The Effect of Echinacea (Immulant ®) in the Treatment of CRYPTOSPORIDIOSIS in Immunocompromised Children (PHASE2)
- The Benefits of Natural Medicine, Vitamin IV Therapy and Supplements: Maintaining Good Health Through Nature
- Parasitic Infections and Ulcerative Colitis: Combining Anti-parasitic and Immunomodulatory Treatments May Achieve Remission (NA)
- Echinaforce COVID-19 Shedding Study (PHASE4)
- Clinical Evaluation of the AP203 Plant Extract Mixture in Adult Patients With Increased Incidence of Viral and/or Bacterial Upper Respiratory Tract Infections (NA)
- Impact of HPV on a Cohort of Southern Italian Women: Epidemiological, Clinical, Morphological and Microbiological Features (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Echinacea purpurea CI brief — competitive landscape report
- Echinacea purpurea updates RSS · CI watch RSS
- University of Washington portfolio CI
Frequently asked questions about Echinacea purpurea
What is Echinacea purpurea?
Echinacea purpurea is a Biologic drug developed by University of Washington.
Who makes Echinacea purpurea?
Echinacea purpurea is developed and marketed by University of Washington (see full University of Washington pipeline at /company/university-of-washington).
What development phase is Echinacea purpurea in?
Echinacea purpurea is FDA-approved (marketed).
Related
- Manufacturer: University of Washington — full pipeline
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing